Dukat M
Department of Medicinal Chemistry, School of Pharmacy, Medical College of Virginia Campus/Virginia Commonwealth University, Richmond 23298-0540, USA.
Curr Opin Investig Drugs. 2001 Mar;2(3):415-8.
Pierre Fabre is developing donitriptan, a piperazide 5-HT1D agonist, as a potential treatment for migraine [175854]. In January 2001, donitriptan had completed phase I trials for migraine and was scheduled to enter phase II development [396027]. This compound has an increased potency and, importantly, markedly higher intrinsic activity in comparison to the well described tryptamine derivatives, naratriptan, zolmitriptan and sumatriptan [295769].
皮埃尔·法布尔公司正在研发多尼普坦，一种哌嗪类5-HT1D激动剂，作为偏头痛的潜在治疗药物[175854]。2001年1月，多尼普坦已完成偏头痛的I期试验，并计划进入II期开发[396027]。与已广为人知的色胺衍生物那拉曲坦、佐米曲坦和舒马曲坦相比，该化合物效力增强，重要的是其内在活性明显更高[295769]。
